CLYM (Climb Bio) Moat Score: 3/10 (As of Jun. 30, 2026)


CLYM Climb Bio Inc CLYM
22 GF Score
Price $13.36
! 2 Warning Signs
View Full Analysis

What is Climb Bio Moat Score?

Climb Bio CLYM +1.52% 22 Moat Score is 3 as of Jun. 30, 2026. GuruFocus rates CLYM with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,401 Biotechnology companies, Climb Bio ranks better than 75.52% on this metric.

Climb Bio has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Climb Bio has No Moat: Climb Bio Inc has very weak competitive advantages. It is in the early stages of development with no significant intellectual property, brand strength, or market leadership.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Climb Bio might have No Moat - Very weak/transient advantages.

Climb Bio  (NAS:CLYM) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Climb Bio Moat Score Related Terms

CLYM vs XOMA, CTMX, ALLO: Moat Score Comparison

For the Biotechnology subindustry, Climb Bio's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Climb Bio Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Climb Bio's Moat Score distribution charts can be found below:

* The bar in red indicates where Climb Bio's Moat Score falls into.


CLYM
22GF Score
Climb Bio Inc CLYM
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Climb Bio (CLYM) has a Moat Score of 3 as of Jun. 30, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Climb Bio ranks #343 out of 1401 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Climb Bio's Moat Score too high?
Climb Bio's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Climb Bio's value of 3 is 50% above this industry median. Based on the distribution chart, Climb Bio ranks #343 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Climb Bio has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Climb Bio's Moat Score compare to XOMA and CTMX?
According to the Biotechnology industry distribution chart, Climb Bio ranks #343 out of 1401 companies for Moat Score. This places Climb Bio in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Climb Bio's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Climb Bio's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Climb Bio's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Climb Bio stock overvalued right now?
Climb Bio (CLYM) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Climb Bio's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Climb Bio (CLYM), the current Moat Score is 3 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Climb Bio Business Description

Address 20 William Street, Suite 145, Wellesley Hills, MA, USA, 02481
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
22GF Score

Get the complete analysis for CLYM

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.36
Price